+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ALPA

Alpa Laboratories Share Price

₹56.58 +0.65 (1.16%)
38.83% Fall from 52W High

09 Nov, 2026 3:50 PM (IST)

Alpa Laboratories live price: ₹56.58. It opened at ₹56 vs previous close ₹56; intraday high/low: ₹58/₹55. The 50 & 200 DMA stand at ₹57.00/₹66.20.

Alpa Laboratories Performance

  • Today's Low
  • ₹55
  • Today's High
  • ₹58
  • 52 Week Low
  • ₹46
  • 52 Week High
  • ₹93
  • Open Price₹56
  • Previous Close₹56
  • Volume27,594
  • 50 DMA₹57.00
  • 100 DMA₹60.50
  • 200 DMA₹66.20

Alpa Laboratories Chart

Investment Returns

  • Over 1 Month -0.72%
  • Over 3 Month -16.9%
  • Over 6 Month -20.04%
  • Over 1 Year -30.35%

Smart Investing Starts Here Start SIP with Alpa Laboratories for Steady Growth!

Invest Now

Alpa Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.1
  • PEG Ratio
  • -0.4
  • Market Cap Cr
  • 119
  • P/B Ratio
  • 0.6
  • Average True Range
  • 3.3
  • EPS
  • 1.7
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.7
  • RSI
  • 55.79
  • MFI
  • 60.8

Latest Stock News Updates

Teradyne eyes India's growing semiconductor testing equipment market

Teradyne expects demand for semiconductor testing equipment to rise as global companies, OSAT firms and chip design startups expand operations in India, says country manager Alpa Sood

Alpa Laboratories Ltd - 532878 - Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September, 2026 Along With Limited Review Report Thereon.

Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve 1. To consider and approve the un-Audited Standalone & Consolidated financial results of the Company for the quarter and half-year ending September 30, 2026. 2. Any other item(s) with the permission of the Chairman.

Alpa Laboratories Ltd - 532878 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Alpa Laboratories Limited hereby submit to the Exchange the Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Prticipants) Regulations, 2018.

Alpa Laboratories Financials

Alpa Laboratories Technicals

EMA & SMA

Current Price
₹56.58
+ 0.65 (1.16%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹54.20
  • 50 Day
  • ₹57.00
  • 100 Day
  • ₹60.50
  • 200 Day
  • ₹66.20

Resistance and Support

56.46 Pivot Speed
  • R3 62.00
  • R2 60.10
  • R1 58.40
  • S1 54.70
  • S2 52.80
  • S3 51.10

Alpa Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-14 Quarterly Results
2026-08-14 Quarterly Results
2026-05-29 Audited Results
2026-02-11 Quarterly Results
2025-11-14 Quarterly Results

Alpa Laboratories Shareholding Pattern

57.19%
42.39%
0.35%
0.07%

About Alpa Laboratories

Alpa Laboratories is engaged in the manufacture of pharmaceutical formulations, including generic, ethical and OTC products for human and veterinary use. View More
  • NSE Symbol
  • ALPA
  • BSE Symbol
  • 532878
  • ISIN
  • INE385I01010

Similar Stocks to Alpa Laboratories

Alpa Laboratories FAQs

Alpa Laboratories share price is ₹56 As on 11 November, 2026 | 06:07

The Market Cap of Alpa Laboratories is ₹119 Cr As on 11 November, 2026 | 06:07

The P/E ratio of Alpa Laboratories is 34.1 As on 11 November, 2026 | 06:07

The PB ratio of Alpa Laboratories is 0.6 As on 11 November, 2026 | 06:07

The 52 week High & Low of Alpa Laboratories is ₹92.5/₹46.1 respectively As on 11 November, 2026 | 06:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23